Table 3 Factors potentially associated with an increased risk of molecular relapse after discontinuation of TKI treatment in CML

From: Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients

Covariate No. patients per group Subhazard ratio (95% CI) P-value
Sex (male vs. female) 113 / 123 1.05 (0.64–1.71) 0.83
Age (> 60 vs. ≤ 60 years) 125 / 111 1.03 (0.63–1.69) 0.87
Sokal risk index (high vs. low-intermediate) 17 / 198 1.54 (0.73–3.25) 0.25
BCR-ABL transcript type (e13a2 vs. e14a2) 70 / 104 0.78 (0.43–1.42) 0.43
History of TKI resistance (yes vs. no) 17 / 219 1.14 (0.43–3.06) 0.28
No. of TKI lines before discontinuation (> 1 vs. 1) 52 / 184 1.21 (0.67–2.2) 0.51
TKI at the time of discontinuation (imatinib vs. others) 175 / 61 0.77 (0.44–1.33) 0.35
Prior exposure to interferon (yes vs. no) 55 / 181 0.53 (0.28–1.01) 0.055
Duration of TKI treatment (< 5 years vs. ≥ 5 years) 19 /217 2.59 (1.33–5.01) 0.005
Time in MR4.5 before discontinuation (< 4 years vs. ≥ 4 years) 82 / 153 2.06 (1.27–3.35) 0.003
  1. CI confidence interval, CML chronic myeloid leukemia, TKI tyrosine kinase inhibitor
  2. Numbers in bold are those with a significant P-value on the statistical analysis (P < 0.05)